Cargando…

PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial

Detalles Bibliográficos
Autores principales:	Malattia, C, Ruperto, N, Palmisani, E, Pederzoli, S, Pistorio, A, Brunner, HI, Cuttica, R, Calvo, I, Garay, SM, Eleftheriou, D, Wouters, C, Wang, J, Devlin, C, Lovell, D, Martini, A, De Benedetti, F, Ravelli, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044553/ http://dx.doi.org/10.1186/1546-0096-11-S2-P147

Ejemplares similares

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
por: De Benedetti, F, et al.
Publicado: (2013)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
por: De Benedetti, F, et al.
Publicado: (2011)

PReS-FINAL-2188: Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study
por: Mirjafari, H, et al.
Publicado: (2013)

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH
por: De Benedetti, F, et al.
Publicado: (2013)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset
por: Ravelli, A, et al.
Publicado: (2014)

Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data
por: Ravelli, A, et al.
Publicado: (2014)

PReS-FINAL-2010: Predictive value of whole-body MRI in juvenile dermatomyositis
por: Malattia, C, et al.
Publicado: (2013)

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
por: Quartier, P, et al.
Publicado: (2013)

PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study
por: De Benedetti, F, et al.
Publicado: (2013)

Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
por: Malattia, Clara, et al.
Publicado: (2020)

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
por: Nirmala, N, et al.
Publicado: (2013)

Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis
por: Palmisani, Elena, et al.
Publicado: (2007)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

PReS-FINAL-2011: Preliminary validation of a new hybrid measure of muscle strength for juvenile dermatomyositis
por: Marafon, D, et al.
Publicado: (2013)

Hemoculture and Polymerase Chain Reaction Using Primers TCZ1/TCZ2 for the Diagnosis of Canine and Feline Trypanosomiasis
por: Eloy, Luciano José, et al.
Publicado: (2012)

Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2014)

PReS-FINAL-2345: Frequency of radiographic damage and progression in individual joints in children with juvenile idiopathic arthritis
por: Giancane, G, et al.
Publicado: (2013)

A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
por: Demirkaya, E, et al.
Publicado: (2011)

Therapeutic approaches for the treatment of new onset and flared juvenile systemic lupus erythematosus with active renal disease: an international multicenter PRINTO study
por: Miettunen, P, et al.
Publicado: (2011)

Mitochondrial and oxidative stress genes are differentially expressed in neutrophils of sJIA patients treated with tocilizumab: a pilot microarray study
por: Omoyinmi, Ebun, et al.
Publicado: (2016)

PReS-FINAL-2040: Outcome of macrophage activation syndrom (MAS) in systemic juvenile idiopatic arthritis (SJIA) in non biologic treated patient
por: Lazarevic, DS, et al.
Publicado: (2013)

P02-029 - CAPS or SJIA
por: Alekseeva, E, et al.
Publicado: (2013)

PReS-FINAL-2129: Whole-body versus localized magnetic resonance imaging in the assessment of juvenile dermatomyositis
por: Madeo, A, et al.
Publicado: (2013)

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre
por: Livermore, P, et al.
Publicado: (2008)

PReS-FINAL-2178: Clinical and microarray follow-up of SJIA patients treated with anakinra over the past 10 years in a single institution
por: Punaro, M, et al.
Publicado: (2013)

PReS-FINAL-2089: Temporomandibular joint involvement and quality of life in juvenile idiopathic arthritis
por: Frid, P, et al.
Publicado: (2013)

2134: Integrating Epidemiology and Biostatistics teaching using the case method
por: Paulus, Jessica K., et al.
Publicado: (2018)

Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
por: Yamaguchi, Ken-ichi, et al.
Publicado: (2012)

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2013)

PReS-FINAL-2184: A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate
por: Ruperto, N, et al.
Publicado: (2013)

Evaluation of the power of six clustering features in identifying a homogeneous disease subset in juvenile idiopathic arthritis (JIA)
por: Magnani, A, et al.
Publicado: (2008)

Development and initial validation of a new short and simple Health-Related Quality Of Life (HRQL) Questionnaire for Pediatric Rheumatic Diseases (PRD)
por: Palmisani, E, et al.
Publicado: (2008)

Impact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritis
por: Meiorin, S, et al.
Publicado: (2008)

Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS)
por: Consolaro, A, et al.
Publicado: (2008)

IL-18 production upon s100 stimulation is reduced in active sJIA patients compared to sJIA patients in remission and healthy controls
por: Haar, Nienke Ter, et al.
Publicado: (2014)

PReS-FINAL-2070: Efficacy of biologic treatments in juvenile idiopathic arthritis with a polyarticular course: an indirect comparison
por: Sawyer, L, et al.
Publicado: (2013)

PReS13-SPK-1576: Unmeet needs in JIA treatment
por: Ruperto, N
Publicado: (2013)

PReS-FINAL-2164: Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis
por: Pignataro, R, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e9ml0gfcjei2b6ahgdkd8c5f08